AU2006342447B2 - Translational dysfunction based therapeutics - Google Patents

Translational dysfunction based therapeutics Download PDF

Info

Publication number
AU2006342447B2
AU2006342447B2 AU2006342447A AU2006342447A AU2006342447B2 AU 2006342447 B2 AU2006342447 B2 AU 2006342447B2 AU 2006342447 A AU2006342447 A AU 2006342447A AU 2006342447 A AU2006342447 A AU 2006342447A AU 2006342447 B2 AU2006342447 B2 AU 2006342447B2
Authority
AU
Australia
Prior art keywords
eif4e
cells
cell
ribavirin
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006342447A
Other languages
English (en)
Other versions
AU2006342447A1 (en
Inventor
Katherine L. B. Borden
Biljana Culjkovic
Gordon A. Jamieson
Alex Kentsis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Therapeutics Inc
Original Assignee
Translational Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Therapeutics Inc filed Critical Translational Therapeutics Inc
Publication of AU2006342447A1 publication Critical patent/AU2006342447A1/en
Assigned to TRANSLATIONAL THERAPEUTICS INC reassignment TRANSLATIONAL THERAPEUTICS INC Amend patent request/document other than specification (104) Assignors: TRANSLATIONAL THERAPEUTICS
Application granted granted Critical
Publication of AU2006342447B2 publication Critical patent/AU2006342447B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006342447A 2005-12-28 2006-12-28 Translational dysfunction based therapeutics Ceased AU2006342447B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US75446105P 2005-12-28 2005-12-28
US60/754,461 2005-12-28
US79404806P 2006-04-22 2006-04-22
US60/794,048 2006-04-22
US84858306P 2006-09-29 2006-09-29
US60/848,583 2006-09-29
US85440406P 2006-10-25 2006-10-25
US60/854,404 2006-10-25
PCT/US2006/049450 WO2007123579A2 (en) 2005-12-28 2006-12-28 Translational dysfunction based therapeutics

Publications (2)

Publication Number Publication Date
AU2006342447A1 AU2006342447A1 (en) 2007-11-01
AU2006342447B2 true AU2006342447B2 (en) 2013-06-20

Family

ID=38625451

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006342447A Ceased AU2006342447B2 (en) 2005-12-28 2006-12-28 Translational dysfunction based therapeutics

Country Status (6)

Country Link
EP (1) EP1971690B1 (enExample)
JP (2) JP2009522281A (enExample)
AU (1) AU2006342447B2 (enExample)
CA (1) CA2633715C (enExample)
NZ (1) NZ569883A (enExample)
WO (1) WO2007123579A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5602349B2 (ja) * 2007-11-20 2014-10-08 旭化成ファーマ株式会社 ミゾリビン及び／又はリバビリンの測定方法
WO2009118712A2 (en) * 2008-03-27 2009-10-01 Ecole Polytechnique Federale De Lausanne (Epfl) Novel dihydroxypyrrolidine derivatives as anti-cancer agents
US8599383B2 (en) 2009-05-06 2013-12-03 The Regents Of The University Of California Optical cytometry
CN103842769B (zh) * 2011-08-02 2017-12-15 加利福尼亚大学董事会 通过活细胞干涉测量法的快速、大量平行单细胞药物响应测量
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
CA2912842C (en) 2013-05-24 2019-03-19 The Regents Of The University Of California Identifying desirable t lymphocytes by change in mass responses
WO2020214806A1 (en) * 2019-04-16 2020-10-22 The Regents Of The University Of California Protein translational control

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1010380A (en) * 1963-08-07 1965-11-17 Shionogi & Co Antibiotic showdomycin and a process for its production
WO1989006132A1 (en) * 1988-01-07 1989-07-13 University Of Liverpool Reverse transcriptase inhibitors for treating adenocarcinomas
WO2001060379A1 (en) * 2000-02-15 2001-08-23 Ribapharm Corp. Nucleoside analogs with carboxamidine modified monocyclic base
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
US20050159372A1 (en) * 2000-02-15 2005-07-21 Robert Tam Nucleoside analogs with carboxamidine modified monocyclic base

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
FI71768C (fi) 1984-02-17 1987-02-09 Orion Yhtymae Oy Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning.
GB8432118D0 (en) 1984-12-19 1985-01-30 Malcolm A D B Sandwich hybridisation technique
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4751177A (en) 1985-06-13 1988-06-14 Amgen Methods and kits for performing nucleic acid hybridization assays
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304620D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
JPH09510601A (ja) 1993-11-12 1997-10-28 ケース・ウエスタン・リザーブ・ユニバーシティ ヒト遺伝子治療用のエピソーム発現ベクター
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
GB9525639D0 (en) 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
US6129705A (en) 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
GB2339817B (en) 1998-07-24 2000-09-27 Schlumberger Holdings Method and apparatus for gravel packing a well
US6135976A (en) 1998-09-25 2000-10-24 Ekos Corporation Method, device and kit for performing gene therapy
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1485396A2 (en) * 2002-02-28 2004-12-15 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
WO2004100995A1 (en) * 2003-05-15 2004-11-25 Hemosol Lp Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1010380A (en) * 1963-08-07 1965-11-17 Shionogi & Co Antibiotic showdomycin and a process for its production
WO1989006132A1 (en) * 1988-01-07 1989-07-13 University Of Liverpool Reverse transcriptase inhibitors for treating adenocarcinomas
WO2001060379A1 (en) * 2000-02-15 2001-08-23 Ribapharm Corp. Nucleoside analogs with carboxamidine modified monocyclic base
US20050159372A1 (en) * 2000-02-15 2005-07-21 Robert Tam Nucleoside analogs with carboxamidine modified monocyclic base
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kentis, A et al (2004) PNAS 101: 18105-18110 *
Sweeney, MJ et al (1973) Cancer Research 33: 2619-2623 *

Also Published As

Publication number Publication date
WO2007123579B1 (en) 2008-04-24
CA2633715C (en) 2016-06-14
AU2006342447A1 (en) 2007-11-01
JP2016040263A (ja) 2016-03-24
CA2633715A1 (en) 2007-11-01
WO2007123579A3 (en) 2008-02-28
WO2007123579A2 (en) 2007-11-01
NZ569883A (en) 2011-12-22
JP2009522281A (ja) 2009-06-11
EP1971690A2 (en) 2008-09-24
EP1971690B1 (en) 2018-10-17
EP1971690A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
US10472677B2 (en) Translational dysfunction based therapeutics
Astudillo et al. The small molecule IMR-1 inhibits the notch transcriptional activation complex to suppress tumorigenesis
JP2022017495A (ja) 癌を治療するための併用療法
Mondello et al. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
Cheng et al. Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer
JP2016040263A (ja) 翻訳機能障害に基づく治療法
US20160113911A1 (en) Methods and compositions for the treatment of cancer
Saito et al. Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor
EP3513192B1 (en) Cell death biomarker
EP3327144B1 (en) Novel androgen receptor mutation
WO2020023768A1 (en) Methods and materials for identifying and treating bet inhibitor-resistant cancers
Ricci et al. Novel ABCG2 antagonists reverse topotecan-mediated chemotherapeutic resistance in ovarian carcinoma xenografts
Gritti et al. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming
Le et al. Design, synthesis, and biological evaluation of potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer
US20240050392A1 (en) Compositions and methods for improved treatment of platinum-based chemotherapeutic resistant tumors
Zhou et al. Chaperone-mediated autophagy regulates the metastatic state of mesenchymal tumors
Njauw et al. Oncogenic KIT induces replication stress and confers cell cycle checkpoint vulnerability in melanoma
JP7684910B2 (ja) 小児対象において神経膠腫を治療するためのｔｇ０２の使用
Class et al. Patent application title: TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS Inventors: Gordon A. Jamieson, Jr.(Arlington, MA, US) Katherine LB Borden (St. Laurent, CA) Biljana Culjkovic (Montreal, CA) Alex Kentsis (New York, NY, US) Assignees: Translational Therapeutics, Inc.
US20220307030A1 (en) Uses of synthetic lethal partners for treatment of cancer
US12161635B2 (en) Compositions and methods of treating PIK3CA helical domain mutant cancers
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
WO2023141648A1 (en) 2-fluoroethyl procarbazine compounds
WO2025199440A1 (en) Methods of treating liposarcoma using a pyrazole compound
WO2024015641A1 (en) Small molecule for treatment of cancer of the appendix

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired